FCGR2A and rheumatoid arthritis: Morales et al. investigated the role of polymorphisms in genes encoding the surface receptors FCGR2A and FCGR3A in influencing the response to tocilizumab and rituximab in 142 patients with RA previously treated with csDMARDs.